News Posts

• Brookline Capital Markets’ Senior Biotechnology Analyst Kemp Dolliver Discusses Bellerophon Therapeutics and Outlook Therapeutics with Bloomberg BNN

• A Note from Brookline Capital Markets Recognizing the Robust Performance of the Genelux Corporation Initial Public Offering

• Genelux IPO

• Apexigen Announces Approximately $2.8 Million Private Placement Financing

• Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note

• IceCure Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

• SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock

• X4 Pharmaceuticals Prices $65.0 Million Public Offering

• CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price

• AGBA ACQUISITION LIMITED COMPLETES BUSINESS COMBINATION WITH TAG HOLDINGS LIMITED